Globus Medical Inc - 2025年季度报告

xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period endedMarch31, 2025or¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) Commission File No.001-35621 GLOBUS MEDICAL, INC.(Exact name of registrant as specified in its charter) DELAWARE04-3744954(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)2560 General Armistead Avenue,Audubon,PA19403-5214(610)930-1800(Address of principal executive offices) (Zip Code)(Registrant’s telephone number, including Area Code) Securities registered pursuant to Section 12(b) of the Act:Title of each classTrading SymbolsName of exchange on which registeredClass A Common Stock, par value $.001 per shareGMEDNew York Stock Exchange Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days: YesxNo¨ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files): YesxNo¨ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act: Large AcceleratedFilerxAccelerated Filer¨Non-acceleratedFiler¨Smaller ReportingCompany¨Emerging GrowthCompany¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):Yes¨Nox The number of shares outstanding of the issuer’s common stock (par value $0.001 per share) as of May 5, 2025 was135,379,373shares. GLOBUS MEDICAL, INC.AND SUBSIDIARIESTABLE OF CONTENTS GLOBUS MEDICAL, INC.AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(Unaudited) Equity: Class A common stock; $0.001par value. Authorized500,000,000shares; issued andoutstanding112,926,345and114,990,219shares at March31, 2025 and December31, 2024,respectively113115Class B common stock; $0.001par value. Authorized275,000,000shares; issued and See accompanying notes to unaudited condensed consolidated financial statements.3 GLOBUS MEDICAL, INC.AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME GLOBUS MEDICAL, INC. AND SUBSIDIARIESNOTES TO CONDENSED CONSOLIDATED STATEMENTS (Unaudited) NOTE 1. BACKGROUND (a) The Company Globus Medical, Inc., together with its majority-owned or controlled subsidiaries, is a medical device company that developsand commercializes healthcare solutions with a mission to improve the quality of life of patients with musculoskeletal disorders. Weare primarily focused on implants that promote healing in patients with musculoskeletal disorders, including the use of a roboticguidance and navigation system and products to treat patients who have experienced orthopedic traumas. We are an engineering-driven company with a history of rapidly developing and commercializing advanced products andprocedures to assist surgeons in effectively treating their patients and to address new treatment options. With numerous productslaunched since the founding of the Company, we offer a comprehensive portfolio of innovative and differentiated technologies thataddress a variety of musculoskeletal pathologies, anatomies, and surgical approaches. We are headquartered in Audubon, Pennsylvania, and market and sell our products through our exclusive sales force in theUnited States, as well as within North, Central & South America, Europe, Asia, Africa and Australia. We sell our products in the U.S.through a sales force comprised primarily of directly-employed and independent sales representatives. Our international sales force iscomprisedof directly-employed sales personnel,independent sales representatives,as well as exclusive and non-exclusive The terms the “Company,” “Globus,” “we,” “us” and “our” refer to Globus Medical, Inc. and, where applicable, ourconsolidated subsidiaries. NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (a)Basis of Presentation The accompanying interim unaudited condensed consolidated financial statements have been prepared in conformity withU.S. Generally Accepted Accounting Principles (“GAAP”) for interim f